Baldness In Young Men Could Be A Risk Factor For BPH

    May 2012 in “ Uro-News ”
    Christine Starostzik
    Image of study
    TLDR Early balding may be a sign of future prostate problems.
    The document suggests that early-onset androgenetic alopecia (AGA) may be an early indicator of future urinary and prostate issues, including benign prostatic hyperplasia (BPH). A Spanish-British case-control study compared 45 men aged between 35 and 65 with early hair loss but no symptoms of urinary obstruction to 42 control subjects. The study found that men with AGA had significantly higher prostate volumes (29.65 ml vs. 20.24 ml), higher International Prostate Symptom Scores (IPSS) (4.94 vs. 1.23), higher prostate-specific antigen (PSA) levels (1.53 vs. 0.94 ng/ml), and lower maximum urinary flow rates (14.5 vs. 22.45 ml/s) compared to controls. Additionally, 48.9% of AGA patients met the diagnostic criteria for BPH, compared to 4.8% in the control group. The study concludes that further research is needed to determine if treating AGA could also benefit accompanying BPH and to investigate the potential increased cardiovascular risk in AGA patients.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

      community Dermatologist told me to quit fin after turning 40

      in Finasteride/Dutasteride  194 upvotes 1 year ago
      A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    6 / 1000+ results